ArticlePloS one2013
Peptidomic Identification of Serum Peptides Diagnosing Preeclampsia.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Exploring the plasma proteome linked to corpus luteum presence and conception mode across pregnancy stages and postpartum.Journal of assisted reproduction and genetics · 2025Article
- PREGNANCY DISORDERS AND MATERNAL CONSEQUENCES: Ethnic disparities in hypertensive disorders of pregnancy.Reproduction (Cambridge, England) · 2025Review
- Association between Apolipoprotein L1 genetic variants and risk of preeclampsia and preterm birth among U.S. Black women.European journal of obstetrics & gynecology and reproductive biology: X · 2025Article
- Preeclampsia prediction and diagnosis: a comprehensive historical review from clinical insights to omics perspectives.Frontiers in medicine · 2025Review
- Molecular epidemiology of pregnancy using omics data: advances, success stories, and challenges.Journal of translational medicine · 2024Review
- Maternal plasma proteome profiling of biomarkers and pathogenic mechanisms of early-onset and late-onset preeclampsia.Scientific reports · 2022Article
- Maternal serum proteomic profiles of pregnant women with type 1 diabetes.Scientific reports · 2022Article
- Serum peptidomic screening identified circulating peptide biomarkers predictive for preeclampsia.Frontiers in cardiovascular medicine · 2022Article
- Joint Associations of Maternal-Fetal APOL1 Genotypes and Maternal Country of Origin With Preeclampsia Risk.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021Article
- A novel peptide promotes human trophoblast proliferation and migration through PI3K/Akt/mTOR signaling pathway.Annals of translational medicine · 2021Article
- Kidney disease and APOL1.Human molecular genetics · 2021Review
- Association of preeclampsia with infant APOL1 genotype in African Americans.BMC medical genetics · 2020Article
- Differential processing of high-molecular-weight kininogen during normal pregnancy.Rapid communications in mass spectrometry : RCM · 2020Article
- Article
- Bioinformatic Analysis of the Wound Peptidome Reveals Potential Biomarkers and Antimicrobial Peptides.Frontiers in immunology · 2020Article
- Arginine vasopressin infusion is sufficient to model clinical features of preeclampsia in mice.JCI insight · 2018Article
- Fetal-Not Maternal-APOL1 Genotype Associated with Risk for Preeclampsia in Those with African Ancestry.American journal of human genetics · 2018Article
- Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia.Frontiers in immunology · 2018Article
- Identification of Kininogen 1 as a Serum Protein Marker of Colorectal Adenoma in Patients with a Family History of Colorectal Cancer.Journal of Cancer · 2018Article
- Alpha-1-antitrypsin functions as a protective factor in preeclampsia through activating Smad2 and inhibitor of DNA binding 4.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We sought to identify serological markers capable of diagnosing preeclampsia (PE). We performed serum peptide analysis (liquid chromatography mass spectrometry) of 62 unique samples from 31 PE patients and 31 healthy pregnant controls, with two-thirds used as a training set and the other third as a testing set. Differential serum peptide profiling identified 52 significant serum peptides, and a 19-peptide panel collectively discriminating PE in training sets (n = 21 PE, n = 21 control; specificity = 85.7% and sensitivity = 100%) and testing sets (n = 10 PE, n = 10 control; specificity = 80% and sensitivity = 100%). The panel peptides were derived from 6 different protein precursors: 13 from fibrinogen alpha (FGA), 1 from alpha-1-antitrypsin (A1AT), 1 from apolipoprotein L1 (APO-L1), 1 from inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), 2 from kininogen-1 (KNG1), and 1 from thymosin beta-4 (TMSB4). We concluded that serum peptides can accurately discriminate active PE. Measurement of a 19-peptide panel could be performed quickly and in a quantitative mass spectrometric platform available in clinical laboratories. This serum peptide panel quantification could provide clinical utility in predicting PE or differential diagnosis of PE from confounding chronic hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.